Board oversight of AI and a cyber programme, but no published approval rules
Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.
1 · Responsibility
Amgen documents board oversight of AI and an AI Governance Council, but publishes no documented AI policy and no approval procedure.
What is documented
- The Corporate Responsibility and Compliance Committee oversees information systems and security including AI and cybersecurity2 3
- The Audit Committee oversees financial systems including their use of AI2 3
- An AI Governance Council sponsored by the Chief Compliance Officer and the SVP AI & Data steers purchased AI services with guardrails and training1
- Since 2026-06-01 an EVP for research, AI and data and an SVP Chief Technology Officer have been in place4 5
- The code of conduct permits only approved AI tools and requires human judgement in decisions on patient safety and regulatory matters7
The case against
Risk management only as a principle
Sources for Responsibility (12)
- Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Amgen Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2026, Annual Meeting 2026-05-19 · 19 May 2026 · primary source
- Amgen Inc. (SEC EDGAR): Definitive Proxy Statement (DEF 14A) 2025 · 23 May 2025 · primary source
- Amgen Inc.: Amgen Announces Retirement of David M. Reese, Executive Vice President and Chief Technology Officer · 22 April 2026 · primary source
- Amgen Inc.: Sean Bruich – Senior Vice President and Chief Technology Officer · 3 November 2026 · secondary source
- Amgen Inc.: Artificial Intelligence Vision · 3 November 2026 · secondary source
- Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
- Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
- Amgen Inc. (Karriereseite): Senior Manager, Responsible AI Governance (job advertisement) · 28 August 2026 · secondary source
- Amgen Inc.: Cybersecurity and Data Privacy (Healthy Amgen) · 3 November 2026 · secondary source
- Amgen Inc.: Amgen Binding Corporate Rules · 3 November 2026 · secondary source
- Amgen Inc.: Code of Conduct (website) · 3 November 2026 · secondary source
2 · Safety
Amgen describes a concrete cyber programme with external review, but a material data incident in 2026 and missing test reports on AI applications stand against this.
What is documented
- The 10-K describes a CISO, a governance council, reviews by internal audit and a biennial external maturity assessment1
- Two hires with false identities were detected and terminated before data was exfiltrated or malware installed1
- In the July 2026 incident, the response plan, containment and external forensics were applied and the incident was reported via 8-K5
- According to Amgen, trained staff review all AI responses of the agent Eva; tests for bias are ongoing3
- Amgen is a member of H-ISAC and trains employees annually on cybersecurity7
The case against
Data incidents
- In July 2026 unauthorised parties stole protected health data from third-party cloud environments; a link to AI is not established5 6
- According to the lawsuit, Amgen acted negligently; the case Humphreys v. Amgen is pending11
- Data on Amgen personnel was taken at the service provider Sirva; according to the notice, Amgen's own systems were not affected8
Sources for Safety (11)
- Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Amgen Inc.: Follow the Data (ATOMIC) · 17 April 2025 · secondary source
- Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
- Bio-IT World: Amgen's AI Futures: Digital Twins, Unstructured Data, Human Review · 3 September 2024 · secondary source
- Amgen Inc. (SEC EDGAR): Form 8-K, Item 1.05 Material Cybersecurity Incidents · 31 July 2026 · primary source
- Amgen Inc. (SEC EDGAR): Form 10-Q for the quarterly period ended June 30, 2026 · 30 June 2026 · primary source
- Amgen Inc.: Cybersecurity and Data Privacy (Healthy Amgen) · 3 November 2026 · secondary source
- ClassAction.org: Amgen Inc. Data Breach (September 2024) – Sirva Relocation · 8 August 2024 · secondary source
- ClaimDepot: Amgen Reports Data Breach Exposes Protected Health Info · 3 August 2026 · secondary source
- Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
- U.S. District Court, Central District of California (via Courthouse News): Complaint, Humphreys v. Amgen Inc., No. 2:26-cv-08688 · 6 August 2026 · primary source
3 · Transparency
Amgen describes AI applications and principles publicly, but discloses no limits, error rates or model information for any of its own systems.
What is documented
- Amgen publicly describes AI applications in research, trials, patient access and office work2 3 4 5
- The 10-K names risks from AI-based systems and faulty AI outputs1
- The agent Eva identifies itself to insurers as an automated system and immediately offers a human4
- Amgen commits to explainability as one of the NIST characteristics of trustworthy AI7
The case against
Missing system information
Informing those affected
- Whether patients are informed about the use of AI is not documented
- The privacy statement contains no statements on AI or chatbots6
Sources for Transparency (9)
- Amgen Inc. (SEC EDGAR): Form 10-K for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Amgen Inc.: Generative AI Tools Support Amgen's Mission to Serve Patients · 7 August 2025 · secondary source
- Amgen Inc.: Follow the Data (ATOMIC) · 17 April 2025 · secondary source
- Amgen Inc.: How Amgen Uses AI to Support Patient Access & Reimbursement · 18 November 2025 · secondary source
- Amgen Inc.: From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation · 22 May 2024 · secondary source
- Amgen Inc.: Privacy Statement (Last Updated December 11, 2024) · 11 December 2024 · secondary source
- Amgen Inc.: Artificial Intelligence Vision · 3 November 2026 · secondary source
- Amgen Inc.: Serving Patients with Integrity: Amgen's Global Code of Conduct (©2026) · 3 November 2026 · secondary source
- NVIDIA: Amgen to Build Generative AI Models for Novel Human Data Insights and Drug Discovery · 8 January 2024 · secondary source
4 · Why the harm rule does not apply
The harm rule does not apply: within the 36-month window there is no judgment, regulatory decision or fine concerning harm caused by Amgen's AI. The 2026 data incident has no established link to AI.
5 · Controversies (2)
- mediumIn July 2026 unauthorised third parties stole data from third-party cloud environments, including protected health data of patients; Amgen classified the incident as material on 2026-07-29, reported it via 8-K and has been sued for negligence in a class action (Humphreys v. Amgen, C.D. Cal.) since 2026-08-06. A link to AI is established neither in the filing nor in the lawsuit. · 31 July 2026 · open
- minorAt the relocation service provider Sirva, data on Amgen personnel (including ID, financial and health information) was accessed from August to October 2023; Amgen informed those affected and the New Hampshire Attorney General in 2024. According to the notice, Amgen's own systems were not affected, and there is no link to AI. · 8 August 2024 · unklar
6 · What remains open
- Outcome of the forensic investigation and cause of the 2026 cloud incident; officially confirmed number of people affected
- Findings by the FDA or EMA on Amgen's AI applications
- Risk classes, approval procedures and metrics of the AI programme
- Information provided to patients about the use of AI
- The 2024 and 2025 sustainability reports could not be retrieved regularly and do not count as evidence
- Contradiction in the company's statements on human review in patient access
7 · How it was assessed
Cut-off date: 3 November 2026 · 43 searches, 35 fetches.
Primary documents read (10)
- Form 10-K FY2025 (Items 1, 1A, 1C)
- Proxy Statement 2026 (complete) and 2025 (up to 100,000 characters)
- Form 8-K Item 1.05 dated 2026-07-31
- Form 8-K Voting Results 2024 and 2025
- Form 10-Q Q2 2026 (Risk Factors)
- Klageschrift Humphreys v. Amgen Inc., No. 2:26-cv-08688 (C.D. Cal.)
- Artificial Intelligence Vision
- Global Code of Conduct (©2026)
- Cybersecurity and Data Privacy, Privacy Statement, Binding Corporate Rules
- Press Release: CTO Leadership Change dated 2026-04-22
Research of 3 November 2026 under Globalance AI Footprint rulebook version 0